Sign in

Malaysia to double AstraZeneca vaccine order through Covax deal

The government has already secured 12.8 million doses from Pfizer Inc-BioNTech SE, it announced an agreement to buy 6.4 million doses directly from Astrazeneca. Is in final negotiations with China’s Sinovac for 14 million doses, CanSino Biologics, and Russia’s Sputnik V vaccine.

Published on: Dec 23, 2020, 15:11:30 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Malaysia is set to secure an additional 6.4 million doses of the Astrazeneca Plc. vaccine through the Covax facility, enough to inoculate 10% of the country’s population, Science and Technology Minister Khairy Jamaluddin said.

Malaysia is struggling to stem a fresh wave of cases that emerged in September and threatens a nascent economic recovery. (REUTERS)
Malaysia is struggling to stem a fresh wave of cases that emerged in September and threatens a nascent economic recovery. (REUTERS)

This will see the Southeast nation doubling its order from the company, with the first batch expected in the second quarter of 2021, Khairy said in a televised briefing Wednesday.

The government is also in final negotiations with China’s Sinovac for 14 million doses, CanSino Biologics for 3.5 million doses, and for 6.4 million shots of Russia’s Sputnik V vaccine made by the Gamelya Research Institute, Khairy said.

“The deals with Sinovac, Cansino, and Gamelya will involve local companies that have been identified based on their ability to work together and to provide fill finish manufacturing capacity for the vaccines,” he said.

Malaysia is struggling to stem a fresh wave of cases that emerged in September and threatens a nascent economic recovery. Daily infections hit a record 2,234 on December 10, with cases erupting at facilities of companies including Top Glove Corp. and Karex Bhd., the world’s biggest producer of condoms.

The government has already secured 12.8 million doses from Pfizer Inc-BioNTech SE in a deal signed last month, and on Tuesday it announced an agreement to buy 6.4 million doses directly from Astrazeneca.

Malaysia has negotiated with Pfizer the option to boost its purchases to cover another 20% of its population, and is in talks with Moderna and Johnson & Johnson, Khairy said.

“I won’t rule out the possibility that we will increase our orders slightly,” he said. “Johnson & Johnson is also a single shot. We like single shot, for obvious reasons. So we are still looking at that.”

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More